Coherus BioSciences

192 articles with Coherus BioSciences

• Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi BiosciencesCoherus received $50 million from sale of 2,491,998 shares at $20.06 per share

  4/20/2021

  Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 stock purchase agreement, Coherus has received $50 million from Junshi Biosciences’ acquisition of 2,491,988 shares at a price per share of $20.06.

• Coherus Management to Present at Upcoming Investor Conferences

  2/25/2021

  Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March.

• Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

  2/24/2021

  Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year

• Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

  2/18/2021

  Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be followed by an investor conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast.

• Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

  2/17/2021

  Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira® (adalimumab) biosimilar product candidate, and has set a Biosimilar User Fee Act action date for December 2021.

• Coherus Announces CFO Transition Plans

  2/16/2021

  Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid Stilwell has been appointed to succeed Dr. Viret as CFO. “It has been a sincere pleasure working with Jean over more than six years as we have built Coherus into a growing commercial-stage biotech company. He will alw

• 

  An Early February Focus on U.S.-Asia Drug Development Deals - UPDATED

  2/3/2021

  Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a...

• Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

  2/2/2021

  A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.  

• Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

  2/1/2021

  Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada

• Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada

  2/1/2021

  Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody

• Coherus BioSciences Announces New Employment Inducement Grants - Jan 22, 2021

  1/22/2021

  Coherus BioSciences, Inc., announced that effective January 21, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares of the common stock of the Company to 3 newly hired non-officer employees, with a per share exercise price of $17.99, the closing trading price on the grant date.

• Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors

  1/7/2021

  Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021. 

• Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST.

• Coherus BioSciences Announced New Employment Inducement Grants

  12/21/2020

  Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 66,000 shares of the common stock of the Company to 5 newly hired non-officer employees, with a per share exercise price of $17.78, the closing trading price on the grant date. The stock options were granted pursu

• Coherus BioSciences Announces New Employment Inducement Grants - Nov 20, 2020

  11/20/2020

  Coherus BioSciences, Inc., announced that effective November 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 140,500 shares of the common stock of the Company to 10 newly hired non-officer employees, with a per share exercise price of $17.92, the closing trading price on the grant date.

• Coherus BioSciences Reports Third Quarter 2020 Financial Results

  11/5/2020

  Coherus BioSciences, Inc., reviewed corporate events and reported financial results for the third quarter and nine months ended September 30, 2020.

• Coherus BioSciences to Report Third Quarter Financial Results on November 5th

  10/22/2020

  - Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update. After releasing third quarter financial results, the Company will post them on the Coherus website at https:/

• Coherus BioSciences Announces New Employment Inducement Grants - Oct 16, 2020

  10/16/2020

  Coherus BioSciences, Inc., announced that effective October 15, 2020, the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to buy 150,000 shares of the Company’s common stock with a per share exercise price of $18.09, the closing trading price on the grant date, and 10,000 restricted stock units.

• Coherus BioSciences Announces New Employment Inducement Grants - Sep 18, 2020

  9/18/2020

  Coherus BioSciences, Inc., announced that effective September 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000 shares of the common stock of the Company to six newly hired non-officer employees, with a per share exercise price of $19.07, the closing trading price on the grant date.

• Coherus BioSciences Announces New Employment Inducement Grants - Aug 21, 2020

  8/21/2020

  Coherus BioSciences, Inc., announced that effective August 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $19.85, the closing trading price on the grant date.